eXoZymes (EXOZ)
NASDAQ:EXOZ
Top Page
eXoZymes
(NASDAQ:EXOZ)
Select Model
Select Model
Rating:46Neutral
Price Target:
$10.00
▼(-12.97% Downside)
Action:ReiteratedDate:04/08/26
The score is primarily held down by weak financial performance (pre-revenue profile, widening losses, and ongoing cash burn with a shrinking balance-sheet cushion). Technicals are mixed—short-term strength but overbought signals and a weaker longer-term trend—while valuation is constrained by negative earnings and no dividend support.
Positive Factors
Pilot-scale validation
A successful 100L pilot demonstrating high conversion, recovery and pharma-grade purity materially reduces technical scale-up risk. This validates the process transferability and enables supply for partner formulation work, supporting longer-term commercial development and de-risking early manufacturing hurdles.
Negative Factors
Pre-revenue business
A multi-year pre-revenue profile means no product-market validation and persistent reliance on development-stage funding. Without a revenue stream, the firm lacks internal cash generation to offset R&D and operating costs, making long-term sustainability dependent on successful commercialization or continual external capital.
Read all positive and negative factors
Positive Factors
Negative Factors
Pilot-scale validation
A successful 100L pilot demonstrating high conversion, recovery and pharma-grade purity materially reduces technical scale-up risk. This validates the process transferability and enables supply for partner formulation work, supporting longer-term commercial development and de-risking early manufacturing hurdles.
Read all positive factors
eXoZymes (EXOZ) vs. SPDR S&P 500 ETF (SPY)
Market Cap
N/A
Dividend YieldN/A
Average Volume (3M)2.40K
Price to Earnings (P/E)―
Beta (1Y)1.24
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees31
SectorTechnology
Sector Strength88
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.32
Shares Outstanding8,478,992
10 Day Avg. Volume1,191
30 Day Avg. Volume2,398
Financial Highlights & Ratios
PEG Ratio-0.19
Price to Book (P/B)26.89
Price to Sales (P/S)0.00
P/FCF Ratio-13.69
Enterprise Value/Market Cap10.00T>
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
eXoZymes Business Overview & Revenue Model
Company Description
eXoZymes, Inc. operates as a synthetic biochemical company in the United States. The company develops SimplePath, a platform that produces chemicals, including pharmaceuticals, fuels, materials, food additives, and novel compounds. Its platform al...
How the Company Makes Money
null...
eXoZymes Financial Statement Overview
Summary
Income Statement
14
Very Negative
Balance Sheet
56
Neutral
Cash Flow
22
Negative
| Breakdown | Dec 2025 | Mar 2025 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | -267.38K | 0.00 | -147.75K | -59.41K |
| EBITDA | -9.43M | -5.59M | -1.60M | -1.18M | -1.15M |
| Net Income | -9.16M | -5.86M | -2.04M | -1.40M | -1.21M |
Balance Sheet | |||||
| Total Assets | 5.97M | 13.03M | 3.56M | 2.69M | 2.35M |
| Cash, Cash Equivalents and Short-Term Investments | 3.04M | 9.72M | 66.53K | 558.57K | 547.81K |
| Total Debt | 1.24M | 1.39M | 1.61M | 608.77K | 720.63K |
| Total Liabilities | 2.57M | 2.61M | 3.94M | 1.31M | 1.15M |
| Stockholders Equity | 3.40M | 10.42M | -384.32K | 1.37M | 1.20M |
Cash Flow | |||||
| Free Cash Flow | -6.67M | -8.90M | -1.47M | -1.44M | -2.01M |
| Operating Cash Flow | -6.50M | -8.51M | -1.18M | -1.26M | -1.59M |
| Investing Cash Flow | -150.22K | -359.22K | -311.17K | -87.21K | -312.25K |
| Financing Cash Flow | -27.71K | 18.52M | 1.00M | 1.36M | 2.31M |
eXoZymes Peers Comparison
UnderperformOutperform
Sector (61)
EXOZ
eXoZymes
11.40
0.50
4.59%
BDRX
Biodexa Pharmaceuticals
3.25
-85.25
-96.33%
ADTX
Aditxt
0.53
-2,602.99
-99.98%
NCEL
NewcelX
2.09
-11.41
-84.52%
VRAX
Virax Biolabs Group Ltd. Class A
0.13
-0.98
-87.93%
eXoZymes Corporate Events
Business Operations and StrategyRegulatory Filings and Compliance
eXoZymes Updates Investor Presentation for NCTx Business
Neutral
Mar 31, 2026
On March 30, 2026, eXoZymes Inc. issued an updated investor presentation for its NCTx business, signaling a refreshed communication of its strategy and operations to the market. The release underscores the company’s effort to provide current...
Business Operations and StrategyProduct-Related Announcements
eXoZymes Reports Successful Pilot-Scale NCT Production Results
Positive
Feb 5, 2026
On January 29, 2026, eXoZymes reported results from a 100-liter pilot production run of N‑trans‑caffeoyltyramine (NCT), a naturally occurring compound of interest in lipid metabolism and energy utilization research, achieving about 99%...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.